OmniAb
NASDAQ: OABIEmeryville, US · Founded 2022 · Delaware corporation
OmniAb provides antibody discovery technologies, including proprietary transgenic animals that generate fully human antibodies, to help biopharmaceutical companies and research institutions identify therapeutic candidates. It offers discovery platforms such as xPloration and licenses its technology to over 100 partners worldwide for clinical drug development.
Founders & leadership
KG
Kurt GustafsonExecutive
MW
Matthew W. FoehrExecutive
CB
Charles BerkmanExecutive
Board
JH
John HigginsBoard director
CR
Carolyn R. BertozziBoard director
JC
Jennifer CochranBoard director
PJ
Philip J. GotwalsBoard director
SL
Steve LoveBoard director
SC
Steve CrouseBoard director
Reported raises · per SEC filings
Form D private placements$30M disclosed across 1 round · 2025
▶$30MraisedSep 2025 · 15 investors · BiotechnologyRule 506(b)
▶$30MraisedSep 2025 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carolyn R. BertozziDirector
- Kurt GustafsonExecutive Officer
- John HigginsDirector
- Jennifer CochranDirector
- Matthew W. FoehrExecutive Officer, Director
- Charles BerkmanExecutive Officer
- Philip J. GotwalsDirector
- Steve LoveDirector
- Steve CrouseDirector
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.8M
- Placement agents
- Leerink Partners LLC
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapAbcam33 shared keywordsSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.
IQVIA30 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Companies competing with OmniAb for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does OmniAb do?
- OmniAb provides antibody discovery technologies, including proprietary transgenic animals that generate fully human antibodies, to help biopharmaceutical companies and research institutions identify therapeutic candidates. It offers discovery platforms such as xPloration and licenses its technology to over 100 partners worldwide for clinical drug development.
- How much funding has OmniAb raised?
- OmniAb has disclosed $30M raised across 1 round.
- Where is OmniAb headquartered?
- OmniAb is headquartered in Emeryville, US.